Bisoprolol
As of the edition of 20 October 2026, Bisoprolol is a small molecule: marketed, first approved in 1986 (FR); acts on ADRB1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2013
- Kind
- Small molecule
- Brand name
- Zebeta
- First approved
- 12 May 1986 (FR)
- Approvals on record
- 12 in 4 regions
- Holder of the most recent approval
- Toa Eiyo Ltd.; 6 holders in all
- Registered trials
- 61, 5 stopped early
- Disease areas
- Heart and blood vessels; Nutrition and metabolism; Hormones; Lungs and airways; Cancer; Chemically induced
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 companies on route B because of this drug.
Companies on route B for this drug
In the product2 companies are on route B because of Bisoprolol.
See the 2 companies on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| ADRB1 | Beta-1 adrenergic receptor | P08588 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 13 | 7 | 2 | 0 |
| Phase 1 | 9 | 6 | 0 | 1 |
| Phase 2 | 5 | 2 | 0 | 1 |
| Phase 3 | 10 | 5 | 2 | 0 |
| Phase 4 | 24 | 14 | 2 | 3 |
| All trials | 61 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Teva | Acquired holder | 2025 to now |
| Mitsubishi Tanabe Pharma | Applicant | |
| Pfizer | Originator | 1992 to 2025 |